
    
      This is a phase II, open-label, non-randomized study that will be conducted in patients
      affected by advanced or metastatic malignant pleural mesothelioma previously treated with no
      more than one systemic therapeutic regimen , that will be conducted using Simon's two-stage
      design method.
    
  